Access cutting-edge acute rejection (ar) of transplanted kidney treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Chicago location
Preparing your pre-screening questions…
Access acute rejection (ar) of transplanted kidney specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acute rejection (ar) of transplanted kidney treatment provided free
Check if you qualify for this acute rejection (ar) of transplanted kidney clinical trial in Chicago, IL
No-Cost Study Care
Local to Chicago
Convenient for IL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term. CAN/IFTA remains a vexing problem for clinicians because current monitoring tools, namely the serum creatinine concentration, are not sensitive to early changes in glomerular filtration rate (GFR) or to histologic damage. Despite advances in prevention of acute rejection (AR), it is still a significant and potentially devastating complication of solid organ transplantation. One strategy to reduce the risk of rejection is to perform kidney biopsies to detect subclinical acute rejection (SCAR) and treat to prevent progression to rejection. There is evidence that treating SCAR can prevent further immune mediated injury to the kidney, a precursor to CAN/IFTA. Kidney biopsies provide better information but are limited due to safety concerns, patient preference and cost issues. Better, early and less invasive markers of CAN/IFTA will allow early intervention as well as improved graft and better patient outcomes. This study seeks to validate specific proteogenomic biomarker panels for AR and CAN/IFTA in a prospective blood, urine and kidney tissue monitoring study of kidney transplant recipients who will be scheduled for standard of care biopsies.
Sponsor: Northwestern University
Yes, this clinical trial (NCT01531257) has an active research site in Chicago, IL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for acute rejection (ar) of transplanted kidney treatment options in Chicago, IL, this clinical trial (NCT01531257) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute rejection (ar) of transplanted kidney specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all acute rejection (ar) of transplanted kidney clinical trials near you to find additional studies recruiting in your area.
See all rheumatoid arthritis clinical trials recruiting in Chicago — not just this study.
Browse Rheumatoid Arthritis Trials in Chicago →